Current status of immune checkpoint inhibitors for gastric cancer

Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with ICI including nivolumab and pembrolizumab has been emerging as a novel treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020-07, Vol.23 (4), p.565-578
Hauptverfasser:	Kono, Koji, Nakajima, Shotaro, Mimura, Kosaku
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Surgery Biomarkers Cancer immunotherapy Cancer Research Clinical aspects Disease control Epstein-Barr virus Gastric cancer Gastroenterology Immune checkpoint inhibitors Immunotherapy Medicine Medicine & Public Health Microsatellite instability Monoclonal antibodies Oncology PD-1 protein PD-L1 protein Pembrolizumab Review Article Surgical Oncology Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!